Radoslava Kostadinova

Lead regional strategy and positioning for oncology and dermatology portfolio including Rituximab, Bevacizumab and Trastuzumab. Drive cross-functional collaboration and work closely with KOLs, hospitals and government institutions to support optimal access, reimbursement and sustainable product positioning within the national oncology framework.

Managed key institutional accounts and KOLs across immunology portfolio including Cibinqo, Enbrel, Ruxience and Xeljanz.

Key Achievement: Achieved and sustained 35% market share for
Cibinqo through focused account strategy, strong stakeholder engagement and effective portfolio execution

Led territory strategy and promotion of Jyseleca, strengthening HCP engagement and contributing to competitive market growth.

Managed specialized portfolio including Miglustat and oncology products. Built strong hospital collaborations and ensured high-quality execution in niche therapeutic areas.

Owned immunology portfolio including Stelara within a highly competitive market environment. Key Achievement: Successfully defended and strengthened product positioning through differentiated strategy, deep disease knowledge and long-term KOL partnerships.